abstract |
The present invention relates to novel peptides that are selective agonists of the type 2 corticotropin release hormone receptor (CRHR2) and their compositions for the treatment, improvement or inhibition of cardiovascular conditions that include, but are not limited to, the heart failure. The novel agonist peptide preferably comprises modifications that include pegylated peptides. In addition, the present invention relates to methods for the treatment and prevention of a disease or disorder related to the activity of CRHR2. |